Developer docs
API playgroundTry for free, no card

Search company profiles

Cube Dx GMBH

Full company profile

uuid000kl8t

Namestring
Cube Dx GMBH
Legal namestring
Cube Dx GmbH
Websiteurl
cubedx.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Cube Dx GmbH is an Austrian molecular diagnostics company headquartered in Sankt Valentin, Austria, founded in 2015 by Christoph Reschreiter (CEO) and Bernhard Ronacher (CSO). The company develops and manufactures multiplex in-vitro diagnostic tests for severe infectious disease, with a primary focus on sepsis pathogen identification directly from whole blood. Its core technology is the hybcell — described as the world's first cylindrical microarray, where DNA oligonucleotides are immobilized on a coated cylindrical surface that rotates through samples during hybridization, intended to improve reproducibility and reduce reaction times. This is paired with the hyborg, a fully automated benchtop instrument that processes hybcell assays without user intervention and includes integrated control and analysis software. The combined 'compact sequencing' workflow links pan-bacterial (16S) and pan-fungal (28S) screening PCR with hybcell-based identification, plus sample preparation kits GINA (whole blood, up to 98% microbial DNA yield) and LINA (extraction-free modulation buffer for BAL and positive blood cultures).

The product portfolio includes CE-IVD certified and IVDR-compliant assays such as the Pathogens xB and Pathogens xC PCR kits for sepsis (covering up to 87 microorganisms and resistance genes in approximately 3 hours from 0.5 mL whole blood), the FungiPlus research-use panel (66 fungal targets), and a SARS-CoV-2 spike mutation screening assay. Cube Dx monetizes through sale of test kits/consumables (pathogen panels, GINA, LINA), instruments (hyborg Dx RED2), and reagents, reporting distributable clinical sensitivity of 74% and specificity of 98% at a limit of detection of 20 CFU/mL. The company has validated its PCR protocols on third-party thermocyclers (Biorad CFX96, Thermo Fisher QuantStudio 3/5) and sample prep instruments (PSS geneLEAD VIII, PSS MagDEA Dx SV).

Go-to-market is exclusively indirect via a network of 8 regional distributors covering 20 countries across Europe plus Jordan (Axon Lab for DACH/Benelux/CEE, Montebello for Nordics, Eurobio Scientific for France, Eurobio DID for Italy, Durviz for Spain, helix2 for Greece, Imogena for Poland, and Al Raseel Supplies for Jordan). Marketing activities are limited to a company blog, LinkedIn presence, and newsletter signup. R&D was supported by H2020 (EU) and FFG (Austria) grants and the company won first place in the Houskappreis 2023 (R&D in SMEs) for compact sequencing, receiving €150,000 of prize money. In 2024 Cube Dx completed its first crowdinvesting campaign on the ROCKETS platform, attracting more than 200 investors to fund European expansion and US market entry preparation. The CEO has publicly stated a near-term revenue target of exceeding €1 million for the first time.

Short descriptiontext

Cube Dx GmbH is an Austrian molecular diagnostics company that develops multiplex in-vitro diagnostic tests for severe infectious diseases — primarily sepsis, pneumonia, and bloodstream infections — using a proprietary cylindrical microarray platform (hybcell) and automated processing instrument (hyborg) sold through European distributors to clinical microbiology laboratories.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSankt Valentin, Austria
HQ citystring
Sankt Valentin
HQ countrystring
Austria
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics, in-vitro diagnostics, clinical microbiology, sepsis diagnostics, infectious disease testing
Industry5 codes
PRIMARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
SECONDARYHLAHAAAC
Microbiology & Infectious Disease Diagnostics (Culture/ID/AST)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAFAMAD
Microbiology & Infectious Disease Testing Laboratories
SECONDARYHLAGAEAI
Sample Logistics, Biorepository & IVD Kit Management (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code4 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
  • Medical and Diagnostic Laboratories6215
  • Medical Laboratories621511
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
  • Laboratory Analytical Instruments3826
Product category
In-Vitro Diagnostics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Molecular Diagnostic Tests and Instruments
TypeHardware Sales
Description

Cube Dx develops, manufactures, and distributes multiplex diagnostic tests and automated instruments for clinical microbiology. Revenue comes from sale of test kits (PCR-boxes, hybcells), instruments (hyborg), and sample preparation reagents (GINA, LINA).

cubedx.com
2Test Kits and Consumables
TypeOne Time License
Description

Products include Pathogens xB, Pathogens xC test kits, hyborg Dx RED2 instruments, and various buffers and reagents for molecular diagnostics.

cubedx.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels8 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1hybcell
Description

The world's first cylindrical microarray - DNA oligos immobilized on a cylindrical coated surface for pathogen identification

cubedx.com
+4 more records
Core offering1 text field

Cube Dx GmbH develops, manufactures, and distributes multiplex molecular diagnostic tests and automated instruments for early detection of severe infections (sepsis, pneumonia, positive blood cultures). Its offering is built on a proprietary cylindrical microarray (hybcell), an automated processing instrument (hyborg), and a compact sequencing workflow that screens 100+ bacterial, fungal, and resistance gene targets in approximately 3 hours from whole blood. Supporting products include sample preparation kits (GINA, LINA) and PCR kits (Pathogens xB/xC) sold to clinical laboratories.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Time to result: 3 hours (vs 48+ hours for traditional culture)
+4 more records
Product overview1 text field

Cube Dx GMBH is a molecular diagnostics company offering a unified platform centered on two core products: the hybcell (world's first cylindrical microarray) and hyborg (automated processing instrument). The workflow relies on compact sequencing technology combining pan-bacterial/pan-fungal PCR screening with hybcell cartridge-based identification. Supporting products include GINA (whole blood sample preparation) and LINA (extraction-free modulation buffer) kits, along with specialized PCR kits (Pathogens xB/xC) and FungiPlus. The company also offers SARS-CoV-2 mutation testing. The platform enables detection of up to 100 microbial species and resistance genes directly from blood samples in approximately 3 hours, compared to traditional culture methods requiring 2+ days.

Product and service10 records
1hybcell
CategoryMicroarray consumable
Description

World's first cylindrical microarray where DNA oligos are immobilized on a coated cylindrical surface. Complementary DNA fragments in samples hybridize with probes, and fluorescence markers make binding visible. The cylindrical design rotates through samples during hybridization for improved reproducibility and reduced reaction times, used by clinical microbiology laboratories for pathogen identification.

2hyborg
CategoryDiagnostic instrument
Description

Fully automated instrument that processes hybcell assays, designed for use in clinical routine laboratories. Provides simple handling and clear reports with automated data analysis and electronic documentation.

3compact sequencing
CategoryDiagnostic workflow
Description

Two-step molecular workflow combining pan-bacterial (16S) and pan-fungal (28S) PCR screening with hybcell cartridge-based identification, enabling detection of approximately 100 bacteria, fungi and resistance genes in a single test with results in approximately 3 hours from whole blood.

4GINA
CategorySample preparation kit
Description

Sample preparation kit for pathogen detection from whole blood. Removes human DNA and enriches microbial DNA for downstream PCR and hybcell analysis, used for sepsis diagnostics from 0.5 mL EDTA whole blood samples.

5LINA
CategorySample preparation reagent
Description

Transfer and modulation buffer enabling direct pathogen detection without DNA extraction, used for BAL samples and positive blood cultures and reducing hands-on time to approximately one minute.

6Pathogens xB
CategoryPCR diagnostic kit
Description

Comprehensive PCR kit for sepsis diagnostics detecting up to 87 microorganisms and resistance genes from whole blood, including pan-bacterial PCR, pan-fungal PCR, and resistance gene screening. Validated for 0.5 mL EDTA blood samples with results in approximately 3 hours.

7Pathogens xC
CategoryPCR diagnostic kit
Description

PCR kit for sepsis diagnostics with enhanced panel coverage, used together with GINA or LINA sample preparation for pathogen identification from various sample matrices.

8FungiPlus
CategoryResearch-use molecular test
Description

Broad molecular fungal identification test for research use detecting 16 fungal genera and 50 fungal species (66 targets total) in approximately 2.5 hours across various sample matrices including blood, BAL, urine, CSF, tissue, skin, nails, and hair.

9CuPCR SARS-CoV-2 Mutations
CategoryViral diagnostic test
Description

RT-PCR test for SARS-CoV-2 mutation analysis based on TaqMan-PCR principles, combined with a hybcell SARS-CoV-2 Mutations assay for epidemiological surveillance, screening 88 SNPs in the S-gene receptor binding domain in under 2 hours total. Marketed for research and epidemiological use only.

10hyborg Dx RED2
CategoryDiagnostic instrument
Description

Specific hyborg instrument model with IVDR declaration of conformity, an automated processing and reporting device for hybcell-based diagnostic assays.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct competitor in rapid molecular sepsis diagnostics from whole blood. T2's T2Bacteria and T2Candida panels target the same clinical microbiology lab customer with culture-independent pathogen ID, making it the closest functional comparator to Cube Dx's compact sequencing workflow.

TypeBroad incumbent
Description

Global IVD incumbent with broad microbiology offerings including the BioFire FilmArray syndromic panels for bloodstream infections and pneumonia. Competes with Cube Dx for the same clinical microbiology lab budget, but with much broader menus and global reach.

TypeBroad incumbent
Description

Market leader in cartridge-based molecular diagnostics (GeneXpert) with installed base in hospital clinical labs worldwide. Competes on rapid infectious disease ID with similar workflow positioning to the hyborg/hybcell platform.

TypeDirect peer
Description

Focused on rapid identification and antimicrobial susceptibility testing directly from positive blood cultures and other samples. Targets the same clinical microbiology customer with culture-to-result acceleration, overlapping with Cube Dx's positive blood culture use case.

TypeBroad incumbent
Description

Major molecular diagnostics and sample preparation player with QIAstat-Dx syndromic panels and broad microbiology offerings. Overlaps with Cube Dx in molecular workflow and sample prep (analogous to GINA/LINA) for infectious disease testing.

TypeBroad incumbent
Description

Provider of MALDI-TOF mass spectrometry (MBT) and molecular microbiology solutions for clinical labs. Competes in clinical microbiology workflow with rapid pathogen ID, including from positive blood cultures, where Cube Dx's compact sequencing also plays.

TypeDirect peer
Description

Earlier-stage molecular microbiology company developing rapid molecular panels for severe infections including sepsis and pneumonia. Closely matches Cube Dx's positioning as a smaller specialist competing against IVD majors with focused infectious disease panels.

TypeDirect peer
Description

Developed the Amplidiag and Novodiag cartridge-based molecular diagnostic platforms for infectious disease and antibiotic resistance; acquired by Hologic. Comparable as a European-origin molecular infectious disease diagnostics platform that scaled into a strategic exit.

TypeDirect peer
Description

Developed the ePlex sample-to-answer molecular diagnostic system for syndromic infectious disease testing; acquired by Roche. Closely mirrors Cube Dx's positioning of an automated cartridge-based molecular platform for clinical microbiology labs.

TypeBroad incumbent
Description

Global IVD leader with broad infectious disease and microbiology portfolio including the cobas Liat and LightCycler systems. Sets the competitive benchmark for hospital molecular microbiology workflows that Cube Dx is targeting.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks3 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cube Dx GMBH

In-Vitro Diagnosticscubedx.com

Cube Dx GmbH is an Austrian molecular diagnostics company that develops multiplex in-vitro diagnostic tests for severe infectious diseases — primarily sepsis, pneumonia, and bloodstream infections — using a proprietary cylindrical microarray platform (hybcell) and automated processing instrument (hyborg) sold through European distributors to clinical microbiology laboratories.

What Cube Dx GMBH does

Cube Dx GmbH is an Austrian molecular diagnostics company headquartered in Sankt Valentin, Austria, founded in 2015 by Christoph Reschreiter (CEO) and Bernhard Ronacher (CSO). The company develops and manufactures multiplex in-vitro diagnostic tests for severe infectious disease, with a primary focus on sepsis pathogen identification directly from whole blood. Its core technology is the hybcell — described as the world's first cylindrical microarray, where DNA oligonucleotides are immobilized on a coated cylindrical surface that rotates through samples during hybridization, intended to improve reproducibility and reduce reaction times. This is paired with the hyborg, a fully automated benchtop instrument that processes hybcell assays without user intervention and includes integrated control and analysis software. The combined 'compact sequencing' workflow links pan-bacterial (16S) and pan-fungal (28S) screening PCR with hybcell-based identification, plus sample preparation kits GINA (whole blood, up to 98% microbial DNA yield) and LINA (extraction-free modulation buffer for BAL and positive blood cultures).

The product portfolio includes CE-IVD certified and IVDR-compliant assays such as the Pathogens xB and Pathogens xC PCR kits for sepsis (covering up to 87 microorganisms and resistance genes in approximately 3 hours from 0.5 mL whole blood), the FungiPlus research-use panel (66 fungal targets), and a SARS-CoV-2 spike mutation screening assay. Cube Dx monetizes through sale of test kits/consumables (pathogen panels, GINA, LINA), instruments (hyborg Dx RED2), and reagents, reporting distributable clinical sensitivity of 74% and specificity of 98% at a limit of detection of 20 CFU/mL. The company has validated its PCR protocols on third-party thermocyclers (Biorad CFX96, Thermo Fisher QuantStudio 3/5) and sample prep instruments (PSS geneLEAD VIII, PSS MagDEA Dx SV).

Go-to-market is exclusively indirect via a network of 8 regional distributors covering 20 countries across Europe plus Jordan (Axon Lab for DACH/Benelux/CEE, Montebello for Nordics, Eurobio Scientific for France, Eurobio DID for Italy, Durviz for Spain, helix2 for Greece, Imogena for Poland, and Al Raseel Supplies for Jordan). Marketing activities are limited to a company blog, LinkedIn presence, and newsletter signup. R&D was supported by H2020 (EU) and FFG (Austria) grants and the company won first place in the Houskappreis 2023 (R&D in SMEs) for compact sequencing, receiving €150,000 of prize money. In 2024 Cube Dx completed its first crowdinvesting campaign on the ROCKETS platform, attracting more than 200 investors to fund European expansion and US market entry preparation. The CEO has publicly stated a near-term revenue target of exceeding €1 million for the first time.

Cube Dx GMBH firmographics

Firmographics
Name
Cube Dx GMBH
Legal name
Cube Dx GmbH
Website
https://cubedx.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Cube Dx GmbH is an Austrian molecular diagnostics company that develops multiplex in-vitro diagnostic tests for severe infectious diseases — primarily sepsis, pneumonia, and bloodstream infections — using a proprietary cylindrical microarray platform (hybcell) and automated processing instrument (hyborg) sold through European distributors to clinical microbiology laboratories.
Ownership category
akta.pro rank

Cube Dx GMBH industry classification

Industry
Product category
In-Vitro Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
SECONDARYHLAHAAAC
Microbiology & Infectious Disease Diagnostics (Culture/ID/AST)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAFAMAD
Microbiology & Infectious Disease Testing Laboratories
SECONDARYHLAGAEAI
Sample Logistics, Biorepository & IVD Kit Management (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Molecular diagnostics
  • In-vitro diagnostics
  • Clinical microbiology
  • Sepsis diagnostics
  • Infectious disease testing

Where Cube Dx GMBH is headquartered

Location

Headquarters

HQ city
Sankt Valentin
HQ country
Austria
HQ region
Europe

Offices1 record

Markets served

Cube Dx GMBH business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Molecular Diagnostic Tests and Instruments: Cube Dx develops, manufactures, and distributes multiplex diagnostic tests and automated instruments for clinical microbiology. Revenue comes from sale of test kits (PCR-boxes, hybcells), instruments (hyborg), and sample preparation reagents (GINA, LINA).
  2. Test Kits and Consumables: Products include Pathogens xB, Pathogens xC test kits, hyborg Dx RED2 instruments, and various buffers and reagents for molecular diagnostics.

Go-to-market motion1 record

Distribution channels8 records

Marketing channels3 records

Cube Dx GMBH product offering

Product offering

Core offering

Cube Dx GmbH develops, manufactures, and distributes multiplex molecular diagnostic tests and automated instruments for early detection of severe infections (sepsis, pneumonia, positive blood cultures). Its offering is built on a proprietary cylindrical microarray (hybcell), an automated processing instrument (hyborg), and a compact sequencing workflow that screens 100+ bacterial, fungal, and resistance gene targets in approximately 3 hours from whole blood. Supporting products include sample preparation kits (GINA, LINA) and PCR kits (Pathogens xB/xC) sold to clinical laboratories.

Product overview

Cube Dx GMBH is a molecular diagnostics company offering a unified platform centered on two core products: the hybcell (world's first cylindrical microarray) and hyborg (automated processing instrument). The workflow relies on compact sequencing technology combining pan-bacterial/pan-fungal PCR screening with hybcell cartridge-based identification. Supporting products include GINA (whole blood sample preparation) and LINA (extraction-free modulation buffer) kits, along with specialized PCR kits (Pathogens xB/xC) and FungiPlus. The company also offers SARS-CoV-2 mutation testing. The platform enables detection of up to 100 microbial species and resistance genes directly from blood samples in approximately 3 hours, compared to traditional culture methods requiring 2+ days.

Differentiator

Problem solved

Functional benefit

Brands

  • hybcell: The world's first cylindrical microarray - DNA oligos immobilized on a cylindrical coated surface for pathogen identification
  • hyborg
  • compact sequencing
  • GINA
  • LINA

Products and services

  • hybcell World's first cylindrical microarray where DNA oligos are immobilized on a coated cylindrical surface. Complementary DNA fragments in samples hybridize with probes, and fluorescence markers make binding visible. The cylindrical design rotates through samples during hybridization for improved reproducibility and reduced reaction times, used by clinical microbiology laboratories for pathogen identification.
  • hyborg Fully automated instrument that processes hybcell assays, designed for use in clinical routine laboratories. Provides simple handling and clear reports with automated data analysis and electronic documentation.
  • compact sequencing Two-step molecular workflow combining pan-bacterial (16S) and pan-fungal (28S) PCR screening with hybcell cartridge-based identification, enabling detection of approximately 100 bacteria, fungi and resistance genes in a single test with results in approximately 3 hours from whole blood.
  • GINA Sample preparation kit for pathogen detection from whole blood. Removes human DNA and enriches microbial DNA for downstream PCR and hybcell analysis, used for sepsis diagnostics from 0.5 mL EDTA whole blood samples.
  • LINA Transfer and modulation buffer enabling direct pathogen detection without DNA extraction, used for BAL samples and positive blood cultures and reducing hands-on time to approximately one minute.
  • Pathogens xB Comprehensive PCR kit for sepsis diagnostics detecting up to 87 microorganisms and resistance genes from whole blood, including pan-bacterial PCR, pan-fungal PCR, and resistance gene screening. Validated for 0.5 mL EDTA blood samples with results in approximately 3 hours.
  • Pathogens xC PCR kit for sepsis diagnostics with enhanced panel coverage, used together with GINA or LINA sample preparation for pathogen identification from various sample matrices.
  • FungiPlus Broad molecular fungal identification test for research use detecting 16 fungal genera and 50 fungal species (66 targets total) in approximately 2.5 hours across various sample matrices including blood, BAL, urine, CSF, tissue, skin, nails, and hair.
  • CuPCR SARS-CoV-2 Mutations RT-PCR test for SARS-CoV-2 mutation analysis based on TaqMan-PCR principles, combined with a hybcell SARS-CoV-2 Mutations assay for epidemiological surveillance, screening 88 SNPs in the S-gene receptor binding domain in under 2 hours total. Marketed for research and epidemiological use only.
  • hyborg Dx RED2 Specific hyborg instrument model with IVDR declaration of conformity, an automated processing and reporting device for hybcell-based diagnostic assays.

Quantifiable outcome

  • Time to result: 3 hours (vs 48+ hours for traditional culture)
  • +4 more outcomes

Companies that use Cube Dx GMBH

Customer profile

Segments1 record

Ideal customer profiles1 record

Cube Dx GMBH technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

Feature5 records

Cube Dx GMBH partnerships and signals

Strategic signal

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

Cube Dx GMBH competitors and assessment

Company assessment

Direct peers

  • T2 Biosystems: Direct competitor in rapid molecular sepsis diagnostics from whole blood. T2's T2Bacteria and T2Candida panels target the same clinical microbiology lab customer with culture-independent pathogen ID, making it the closest functional comparator to Cube Dx's compact sequencing workflow.
  • Accelerate Diagnostics: Focused on rapid identification and antimicrobial susceptibility testing directly from positive blood cultures and other samples. Targets the same clinical microbiology customer with culture-to-result acceleration, overlapping with Cube Dx's positive blood culture use case.
  • Curetis / OpGen: Earlier-stage molecular microbiology company developing rapid molecular panels for severe infections including sepsis and pneumonia. Closely matches Cube Dx's positioning as a smaller specialist competing against IVD majors with focused infectious disease panels.
  • Mobidiag (Hologic): Developed the Amplidiag and Novodiag cartridge-based molecular diagnostic platforms for infectious disease and antibiotic resistance; acquired by Hologic. Comparable as a European-origin molecular infectious disease diagnostics platform that scaled into a strategic exit.
  • GenMark Diagnostics (Roche): Developed the ePlex sample-to-answer molecular diagnostic system for syndromic infectious disease testing; acquired by Roche. Closely mirrors Cube Dx's positioning of an automated cartridge-based molecular platform for clinical microbiology labs.

Broad incumbents

  • bioMérieux: Global IVD incumbent with broad microbiology offerings including the BioFire FilmArray syndromic panels for bloodstream infections and pneumonia. Competes with Cube Dx for the same clinical microbiology lab budget, but with much broader menus and global reach.
  • Cepheid (Danaher): Market leader in cartridge-based molecular diagnostics (GeneXpert) with installed base in hospital clinical labs worldwide. Competes on rapid infectious disease ID with similar workflow positioning to the hyborg/hybcell platform.
  • Qiagen: Major molecular diagnostics and sample preparation player with QIAstat-Dx syndromic panels and broad microbiology offerings. Overlaps with Cube Dx in molecular workflow and sample prep (analogous to GINA/LINA) for infectious disease testing.
  • Bruker Microbiology: Provider of MALDI-TOF mass spectrometry (MBT) and molecular microbiology solutions for clinical labs. Competes in clinical microbiology workflow with rapid pathogen ID, including from positive blood cultures, where Cube Dx's compact sequencing also plays.
  • Roche Diagnostics: Global IVD leader with broad infectious disease and microbiology portfolio including the cobas Liat and LightCycler systems. Sets the competitive benchmark for hospital molecular microbiology workflows that Cube Dx is targeting.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks3 records

Key highlights7 records

Customer concentration

Cube Dx GMBH social profiles

Digital presence

Cube Dx GMBH compliance and trust

Trust signal

Compliance3 records

Cube Dx GMBH financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cube Dx GMBH leadership team

Management profile

Number of profiles

Profiles2 records

Cube Dx GMBH funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cube Dx GMBH M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cube Dx GMBH

What does Cube Dx GMBH do?

Cube Dx GmbH develops, manufactures, and distributes multiplex molecular diagnostic tests and automated instruments for early detection of severe infections (sepsis, pneumonia, positive blood cultures). Its offering is built on a proprietary cylindrical microarray (hybcell), an automated processing instrument (hyborg), and a compact sequencing workflow that screens 100+ bacterial, fungal, and resistance gene targets in approximately 3 hours from whole blood. Supporting products include sample preparation kits (GINA, LINA) and PCR kits (Pathogens xB/xC) sold to clinical laboratories.

Is Cube Dx GMBH a public or private company?

Cube Dx GMBH is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Cube Dx GMBH founded?

Cube Dx GMBH was founded in 2015. It employs 1 to 10 people.

Where is Cube Dx GMBH based?

Cube Dx GMBH is headquartered in Sankt Valentin, Austria, in the Europe region.

How does Cube Dx GMBH make money?

Two revenue lines are on record. Molecular Diagnostic Tests and Instruments are the primary driver. The others are test Kits and Consumables.

Who are Cube Dx GMBH's main competitors?

Direct peers on record are T2 Biosystems, Accelerate Diagnostics, Curetis / OpGen, Mobidiag (Hologic) and GenMark Diagnostics (Roche). Broad incumbents are bioMérieux, Cepheid (Danaher), Qiagen, Bruker Microbiology and Roche Diagnostics.

Does Cube Dx GMBH have an API?

No public API is recorded for Cube Dx GMBH.

What industry is Cube Dx GMBH in?

Cube Dx GMBH's product category is In-Vitro Diagnostics. Its primary akta.pro industry code is HLAAALAC, Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels), with a secondary code of HLAHAAAC, Microbiology & Infectious Disease Diagnostics (Culture/ID/AST). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales